

The Initiative's Research Grants Program

The Liddy Shriver Sarcoma Initiative supports research that is targeted at finding a cure for sarcoma, as well as research that attempts to develop more effective treatment regimens than those currently available. Specifically, the Initiative funds seed grants for basic and translational research on sarcomas. We anticipate that the results of these “starter grants” will allow researchers to apply for funding for larger studies.

Our Research Grants Program is highly selective: applications are accepted throughout the year and are reviewed by sarcoma experts. Only the most promising studies are approved through this process, and our goal is to ensure that funds are available for every approved study.

The Initiative has funded more than \$1.7 million in sarcoma research studies by respected investigators around the world.

At the Initiative, we believe that quality research should be funded wherever it is done, and we encourage collaborative efforts between departments, institutions and countries. We hope that such collaborative studies will bring more effective and less invasive treatments from the research lab to the patient quicker than has been possible in the past. We also hope that such grants provide a mechanism and incentive for other sarcoma researchers to undertake similar international collaborative efforts.

“I have been very impressed by your grant funding program. You have done an excellent job engaging the best minds in the sarcoma research field to act as peer reviewers, thus assuring that grant applications are fairly reviewed and only the best proposals are funded.”

- David Loeb, MD, PhD; Director of the Musculoskeletal Tumor Program; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The Initiative has awarded grants to investigators in Australia, Canada, China, Germany, France, Italy, the Netherlands, Norway and the USA. These grants have focused on several types of sarcoma, including alveolar soft part sarcoma, carcinosarcoma, chondrosarcoma, chordoma, clear cell sarcoma, Ewing's sarcoma, GIST, leiomyosarcoma, liposarcoma, malignant peripheral nerve sheath tumor, osteosarcoma, rhabdomyosarcoma and unclassified pleomorphic sarcoma (MFH).

Recipients of the Initiative's grants agree to publish both an experimental plan and a study report in ESUN.

These reports allow physicians and researchers worldwide to benefit from learning about the research we have funded. We are proud of this level of transparency and accountability, and we believe that donors have a right to know how their money is used. In keeping with our donors' wishes, the Initiative's grants may not be used for salaries, overhead or indirect costs of the investigators' institutions.

Learn more about the Research Grants Program at SarcomaHelp.org.

Physicians and Researchers Support the Initiative's International Efforts

“The Liddy Shriver Sarcoma Initiative is the most important non-governmental organization, surpassing the patient advocacy mission and supporting research and collaboration in the sarcoma field. **The Initiative's collaborating partners belong to the most reliable sarcoma specialists in the world.** -- Piotr Rutkowski, MD, PhD;
Head of the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland



“The vision of the Initiative in promoting international collaborating has already proven important in our understanding of sarcoma by allowing researchers to pool critical resources, especially clinical specimens, to generate information that has sufficient statistical power. I think the projects supported by the Initiative and the successes we have had are the best testimony for the critical role of international collaboration. **We look forward to making sarcoma history with Liddy Shriver Sarcoma Initiative.**”
-- Wei Zhang, PhD; *Director, Cancer Genomics Core Lab at MD Anderson Cancer Center*

International cooperation among the entire spectrum of sarcoma experts, from dedicated laboratory researchers to diagnostic and treating physicians of all specialties, is critical to achieve the best results for individual patients. **No one country has all the answers, and we can only improve by being open to ideas developed by experts elsewhere.** -- Raphael Pollock, MD, PhD; *Senator A. M. Aiken, Jr. Distinguished Chair; University of Texas MD Anderson Cancer Center*

“The Liddy Shriver Sarcoma Initiative is a focus for the brain, heart and soul of the sarcoma community, providing essential resources for scientists, physicians, caregivers, patients and advocates. **The Initiative breaks barriers to cooperation and communication with open access to their authoritative reviews, extensive translations, and funding of joint research projects emanating from transcontinental and transnational collaboration.**” -- Crystal Mackall, MD; *Chief of the Pediatric Oncology Branch of the National Cancer Institute*

Moving from bench to bed-side will be the most successful way to improve patient treatment and management. **The Liddy Shriver Sarcoma Initiative fosters this type of collaboration by bringing together leading basic biologists, pathologists and translational oncologists in common research projects - ultimately accelerating sarcoma research.**” -- Leonardo A. Meza-Zepeda, PhD; *Head of the Microarray and Sequencing Core Facility at the Norwegian Radium Hospital*

“**The Initiative's successful fundraising efforts have led to numerous seed-funded projects; in our case, that seed sprouted a fruit-bearing tree.**” -- Jeffrey Toretsky, MD; *Georgetown University Lombardi Cancer Center in Washington, DC*



**Learn more about the Initiative's Global
Research Grants Program at SarcomaHelp.org.**